Metamizol Zentiva

Metamizole, the active ingredient in Metamizol Zentiva, is a pyrazolone presented as an oral formulation for oral use. It provides analgesic and antipyretic effects for the relief of pain and fever in adult patients.

GNH USA supplies Metamizol Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets across the European Union and other regions. The company adheres to stringent quality standards, maintains robust logistics where required, and offers comprehensive documentation to support import and regulatory compliance for its clients.

Metamizole is used in the management of pain and fever, acting within the pyrazolone analgesic class. - Pain: Provides rapid relief of moderate to severe acute pain. - Fever: Reduces elevated body temperature in febrile conditions. - Postoperative pain: Controls pain following surgical procedures.

Metamizole may be associated with a range of adverse reactions, varying from mild to potentially serious. Common Side Effects: - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness. - Rash: mild skin erythema. Serious or Rare Side Effects: - Agranulocytosis: severe reduction of white blood cells. - Severe allergic reactions: anaphylaxis or angioedema. - Stevens‑Johnson syndrome: rare severe skin reaction.

When prescribing Metamizole, several precautions should be observed to minimize risk. - Monitor blood counts: regular complete blood count testing is advised. - Assess infection risk: watch for signs of infection due to possible neutropenia. - Use cautiously in renal or hepatic impairment: dose adjustment may be required. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Pregnancy and lactation: consider potential risks and consult guidelines. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Metamizole can interact with other medicines; awareness of these interactions helps ensure safe use. Major Interactions (Avoid): - Concurrent myelotoxic agents: may increase risk of severe blood disorders. - Methotrexate: can enhance toxicity and bone marrow suppression. Moderate Interactions (Monitor Closely): - NSAIDs: may augment gastrointestinal irritation. - Anticoagulants: potential for altered bleeding risk. - ACE inhibitors or diuretics: monitor blood pressure for additive hypotensive effect.